XLO
Xilio Therapeutics Inc

1,670
Mkt Cap
$35.76M
Volume
1.45M
52W High
$1.70
52W Low
$0.615
PE Ratio
-0.99
XLO Fundamentals
Price
$0.65
Prev Close
$0.6811
Open
$0.69
50D MA
$0.7673
Beta
0.74
Avg. Volume
799,384.37
EPS (Annual)
-$1.09
P/B
-4.16
Rev/Employee
$99,125.00
Loading...
Loading...
News
all
press releases
News Placeholder
Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates
Xilio Therapeutics (XLO) delivered earnings and revenue surprises of 0.00% and -28.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates
BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of -41.56% and -34.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Xilio Stock Jumps 8% On Cancer Drug Data; Gilead Boost Extends Cash Runway Into 2027 — Retail Says Stock Undervalued
The company has begun dosing patients in Phase 2 of its trial for XTX301, a tumor-activated IL-12 therapy that showed two partial responses in early testing and was generally well tolerated.
Stocktwits·3mo ago
News Placeholder
Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates
Xilio Therapeutics (XLO) delivered earnings and revenue surprises of -100.00% and -10.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
<
...
1
>

Latest XLO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.